QV Bioelectronics USA cooperation feasibility study

点击翻译按钮获取中文摘要

Glioblastoma is the most common and aggressive primary adult brain cancer. Global incidence is 3-5/100,000 persons and rising, with c.3000 UK diagnoses/year. There is no cure and patient life expectancy is just 14-months post-diagnosis on average.Electric field therapy is a new form of cancer treatment applied after tumour resection that directly interferes with cell division, slowing tumour recurrence and prolonging life. However, the single marketed device for glioblastoma is not recommended for use on the NHS by NICE due to poor patient quality-of-life and low cost-effectiveness.QV Bioelectronics (QVB) are developing GRACE, a novel implant that delivers electric field therapy in a focal and continuous manner, potentially doubling glioblastoma patient life expectancy, leading to potential improved patient outcomes whilst overcoming quality-of-life issues associated with existing solutions. QVB is seeking to access partners in the US who have specialist knowledge, technologies and capital available to bring the GRACE device to market. QVB's device is still undergoing pre-clinical development and will not be ready to be prescribed to patients for several years. QVB's technology will be expanded to other types of brain tumours in future, creating a combined global market opportunity worth over £5Bn/year, whilst providing a new treatment for NHS patients. This will generate UK jobs and help to cement the UK's position as global leaders in the growing field of bioelectronics.